- Home
- ACR vs TLSI Comparison
ACR vs TLSI Comparison
Compare ACR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- TLSI
- Stock Information
- Founded
- ACR 2005
- TLSI 2010
- Country
- ACR United States
- TLSI United States
- Employees
- ACR N/A
- TLSI N/A
- Industry
- ACR Real Estate Investment Trusts
- TLSI Medical Specialities
- Sector
- ACR Real Estate
- TLSI Health Care
- Exchange
- ACR Nasdaq
- TLSI Nasdaq
- Market Cap
- ACR 136.9M
- TLSI 150.3M
- IPO Year
- ACR N/A
- TLSI N/A
- Fundamental
- Price
- ACR $17.68
- TLSI $4.93
- Analyst Decision
- ACR Buy
- TLSI Strong Buy
- Analyst Count
- ACR 2
- TLSI 6
- Target Price
- ACR $17.50
- TLSI $11.75
- AVG Volume (30 Days)
- ACR 16.4K
- TLSI 33.1K
- Earning Date
- ACR 02-26-2025
- TLSI 11-14-2024
- Dividend Yield
- ACR N/A
- TLSI N/A
- EPS Growth
- ACR N/A
- TLSI N/A
- EPS
- ACR 0.83
- TLSI N/A
- Revenue
- ACR $77,437,000.00
- TLSI $26,891,000.00
- Revenue This Year
- ACR N/A
- TLSI $60.96
- Revenue Next Year
- ACR N/A
- TLSI $53.65
- P/E Ratio
- ACR $21.25
- TLSI N/A
- Revenue Growth
- ACR 8.77
- TLSI 67.90
- 52 Week Low
- ACR $9.47
- TLSI $3.50
- 52 Week High
- ACR $17.78
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- ACR 62.15
- TLSI 56.22
- Support Level
- ACR $17.00
- TLSI $4.53
- Resistance Level
- ACR $17.66
- TLSI $4.92
- Average True Range (ATR)
- ACR 0.42
- TLSI 0.29
- MACD
- ACR 0.12
- TLSI -0.02
- Stochastic Oscillator
- ACR 95.22
- TLSI 50.63
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.